Enveric Biosciences (NASDAQ: ENVB) furnishes Q2 2026 investor presentation

Filing Impact

(High)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Enveric Biosciences, Inc. furnished a Q2 2026 investor presentation under Regulation FD. The company plans to post this Investor Presentation on its website and use it in discussions with current and potential investors, analysts, lenders, business partners, acquisition candidates, customers, and employees.

The Investor Presentation is attached as Exhibit 99.1 and is also accessible via the company’s investor events webpage. The information in this report, including Exhibit 99.1, is furnished rather than filed under the Exchange Act, limiting its treatment under Section 18 and other incorporation-by-reference provisions.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Terms

Regulation FD, Investor Presentation, emerging growth company, Exhibit 99.1

4 terms

Regulation FD regulatory

"Item 7.01 Regulation FD Disclosure."

Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.

Investor Presentation financial

"the Company has prepared presentation materials (the “Investor Presentation”) that management intends to release"

An investor presentation is a carefully prepared talk or visual display that explains a company's business, goals, and financial performance. It helps investors understand how the company operates and its future prospects, much like a report card or progress update. These presentations are important because they provide transparency and help investors decide whether to support or invest in the company.

emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Exhibit 99.1 regulatory

"Investor Presentation Q2 2026 (furnished pursuant to Item 7.01)"

Exhibit 99.1 is a label used in regulatory filings to identify a specific attached document, most often a company press release or investor presentation filed with securities regulators. For investors it matters because it marks an official, contemporaneous source of information directly tied to a filing—like the original news article pinned to a legal record—so traders and analysts treat it as an authoritative statement that can move a stock or clarify a company’s situation.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

06/08/2026 - 05:53 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

June 8, 2026

Date of Report (Date of earliest event reported)

Enveric Biosciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-38286

95-4484725

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

Enveric Biosciences, Inc.

245 First Street , Riverview II, 18th Floor

Cambridge, MA, 02142

(Address of principal executive offices) (Zip code)

Registrant’s telephone number, including area code: (617) 444-8400

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.01 per share		ENVB		The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

Enveric Biosciences, Inc. (the “Company”) has prepared presentation materials (the “Investor Presentation”) that management intends to release on its website on or about June 8, 2026. From time to time thereafter, the Company may use the Investor Presentation, possibly with modifications, in presentations to current and potential investors, analysts, lenders, business partners, acquisition candidates, customers, employees, and others with an interest in the Company and its business.

A copy of the Investor Presentation is furnished as Exhibit 99.1 to this report and incorporated here by reference. A copy of the Investor Presentation is also available via the Company’s website at https://www.enveric.com/investors/events/. Materials on the Company’s website are not part of or incorporated by reference into this report.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Investor Presentation Q2 2026 (furnished pursuant to Item 7.01)
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 8, 2026	ENVERIC BIOSCIENCES, INC.

	By:	/s/ Joseph Tucker
		Joseph Tucker, Ph.D.
		Chief Executive Officer

Exhibit 99.1

Source: View Original Filing on SEC EDGAR

FAQ

What did Enveric Biosciences (ENVB) disclose in this 8-K?

Enveric Biosciences furnished a Q2 2026 Investor Presentation under Regulation FD. The presentation will be used in communications with investors, analysts, lenders, business partners, acquisition candidates, customers, employees, and other interested parties, and is attached as Exhibit 99.1 to the report.

What is Enveric Biosciences' Q2 2026 Investor Presentation?

The Q2 2026 Investor Presentation is a set of materials Enveric’s management prepared for investors and other stakeholders. It is furnished as Exhibit 99.1 to this report and is intended for use in ongoing presentations about the company and its business activities.

Is the Enveric Biosciences Investor Presentation considered filed with the SEC?

No. The company states the information in this report, including Exhibit 99.1, is furnished under Regulation FD. It is not deemed filed for Section 18 of the Exchange Act and is not incorporated into other filings unless specifically referenced there.

Where can investors access Enveric Biosciences' Q2 2026 Investor Presentation?

Investors can access the Q2 2026 Investor Presentation as Exhibit 99.1 to this report. Enveric also makes it available on its website at the investors events section, providing another way for interested parties to review the same materials.

Does this Enveric Biosciences 8-K include financial statements?

This report lists only exhibits under Item 9.01, including the Q2 2026 Investor Presentation and the cover page interactive data file. It does not attach separate financial statements as part of the exhibit list disclosed here.

How will Enveric Biosciences use the Q2 2026 Investor Presentation?

Enveric plans to use the Investor Presentation in meetings with current and potential investors, analysts, lenders, business partners, acquisition candidates, customers, employees, and others. The company may modify the materials over time while continuing to use them for these audiences.

Filing Exhibits & Attachments

19 documents